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ABSTRACT 
 
RNA Interference has rapidly emerged as an efficient procedure for knocking down gene expression in model systems. 
However, cross-reactivity, whereby multiple genes may be simultaneously targeted by a single short interfering RNA 
(siRNA), can potentially jeopardize correct interpretation of gene function. As such, it is essential to test the specificity 
of a siRNA prior to a full phenotypic analysis. To this end, we have adapted a reporter-based assay harnessing the 
sensitivity of luciferase activity to provide a quantitative readout of relative RNAi efficacy and specificity. We have 
tested different siRNAs directed against Thymosin β4 (Tβ4); determined their effectiveness at silencing Tβ4 and have 
both excluded off-target silencing of the Tβ4 homologue Thymosin β10 (Tβ10) and demonstrated partial knockdown of 
Tβ10 despite significant (12/23; 52%) sequence mismatch. This assay system is applicable to any RNAi study where 
there is a risk of targeting homologous genes and to the monitoring of off-target effects at the genome level following 
microarray expression profiling. 
 
 
INTRODUCTION 
 
The ability to selectively abolish expression of a single 
gene and to examine the resulting cellular phenotype has 
enabled substantial progress in the understanding of 
gene function. Despite the reported problems of cross-
reactivity (1) and induction of an interferon response (2), 
RNA interference (RNAi) has rapidly become the 
preferred technique for abolishing gene expression. 
 
RNAi, which occurs endogenously in eukaryotes, is 
initiated by the cleavage of long dsRNA into 21-23 
nucleotide siRNA, by the RNase III endonuclease, Dicer. 
The siRNAs are incorporated into a multisubunit RNA-
induced silencing complex (RISC), which targets 
complementary mRNA for degradation. 
 
The extent of target specificity offered by RNAi in 
mammalian cells is still highly controversial and is 
almost certainly sequence-dependent. Many groups 
report a high degree of specificity, such as the ability of 
siRNAs to discriminate between wild type and mutant 
p53, differing by a single nucleotide, in H1299 and U20S 
cells (3). Genome-wide microarray studies have 
attempted to resolve the matter, but have proven equally 
inconclusive (1, 4-6). Specific silencing was observed 
when an exogenously expressed protein, EGFP, was 
targeted in HEK 293 cells (5). However, a conflicting 
study in HeLa cells demonstrated that RNAi targeting 
two different genes, IGF1R and MAPK14, resulted in 
silencing of non-targeted genes containing as few as 
eleven nucleotides of identity (1). Disparity between 
these two data sets could be explained by the fact that 
EGFP is not an endogenous mammalian gene and, 
therefore, siRNAs directed towards IGF1R and MAPK14 
would be expected to share sequence homology with a 
greater number of mammalian genes than a siRNA to 
target EGFP and carry a greater risk of off-target     
 
 
Smart et al. - A rapid and sensitive assay for quantification of siRNA efficiency and specificity 
www.biologicalprocedures.com 
2 
silencing. Either way it appears that there are intrinsic 
limits on the specificity of RNAi. In a recent study 
examining 359 published siRNA sequences, it was found 
that approximately 75% have a risk of non-specific 
targeting (7). Furthermore, siRNAs can illicit non-specific 
effects at the level of protein synthesis without a 
c o r r e s p o n d i n g  e f f e c t  o n  m R N A  l e v e l s  ( 8 )  i n  a  m a n n e r  
analogous to that observed with micro RNAs (miRNAs) 
(9-10). 
 
Clearly, so-called off-target gene silencing could 
represent a significant problem, resulting in RNAi 
adversely targeting multiple genes simultaneously. It is, 
therefore, essential to determine which genes, if any, 
share significant sequence identity with the proposed 
siRNA and to directly assess whether their expression is 
altered by the siRNA. 
 
Our RNAi studies have been based upon the targeting of 
the actin binding protein Thymosin beta 4 (Tβ4). We 
have encountered significant difficulties, such as probe 
cross-reactivity and non-specific product detection, using 
conventional methods, in assessing the specificity of Tβ4 
knockdown as against a non-specific effect on its closest 
relative Thymosin beta 10 (Tβ10). This is a potential 
problem associated with detecting expression levels 
following RNAi of many similarly sized, highly 
homologous genes and/or members of the same gene 
family. 
 
In this study we present a reporter-based assay system to 
test both the efficacy and specificity of Tβ4 knockdown, 
which can be applied in general to other siRNAs. We 
have placed target sequences for either Tβ4 or Tβ10 
downstream of a luciferase gene and following co-
transfection of the relevant siRNA assessed specific 
knockdown via a quantitative reduction in luciferase 
activity. 
 
MATERIALS AND METHODS 
 
Construction of Tβ4 shRNAs  
 
Tβ4 shRNA constructs were prepared by modifying a 
RasGAP shRNA transgene (11), kindly provided by 
G.Gish, which uses the human H1 RNA polymerase III 
to drive transcription of short hairpin RNA (shRNA) 
targeting the p120-Ras GTPase-activating protein 
(RasGAP). The RasGAP shRNA sequence was removed 
from the transgene by digest with Asp718 and XbaI, to 
leave a pcDNA3.1 (+) backbone (Invitrogen) containing 
the pol III promoter. The target Tβ4 shRNA sequences, 
u n d e r l i n e d  i n  F i g u r e  1 ,  w e r e  p r e p a r e d  b y  
oligonucleotide synthesis: 5’-
GTACCCTGAGATCGAGAAATTCGATAAGTTCAAGA
GACTTATCGAATTTCTCGATCTCAGTTTTTGGAAAT-
3’ (Tβ4 shRNA1, sense strand); 5’-
CTAGATTTCCAAAAACTGAGATCGAGAAATTCGAT
AAGTCTCTTGAACTTATCGAATTTCTCGATCTCAGG
–3’ (Tβ4 shRNA1, antisense strand); 5’-
GTACCAGAAGCAAGCTGGCGAATCGTAATTCAAG
AGATTACGATTCGCCAGCTTGCTTCTTTTTTGGAAA
T–3’ (Tβ4, shRNA2, sense strand); 5’-
CTAGATTTCCAAAAAAGAAGCAAGCTGGCG
AATCGTAATCTCTTGAATTACGATTCGCCAG
CTTGCTTCTG–3’ (Tβ4 shRNA2, antisense strand). 
Oligonucleotides were annealed by heating to 90°C in 
the presence of 50mM NaCl and gradual cooling to room 
temperature. Double stranded oligonucleotides were 
introduced into the Asp718 and XbaI sites of pcDNA3-H1 
pol III. 
 
Fig. 1: Tβ4 and Tβ10 share a high degree of sequence homology. An 
alignment of Tβ4 and Tβ10 coding sequences, using ClustalW (MRC 
RFCGR, http://www.rfcgr.mrc.ac.uk/Registered/Option/clustal.html). 
Sequences selected for Tβ4 shRNA constructs, on the basis of lower 
homology with Tβ10, are underlined. 
 
Generation of β-thymosin reporter constructs 
 
Oligonucleotides were synthesised to include the 23nt 
target sequence along with 38nt of flanking sequence: 5’-
CAAGGATGTCTGACAAACCCGATATGGCTGAGATC 
GAGAAATTCGATAAGTCGAAGTTGAAGAAAACAGAA
C–3’ (Tβ4 reporter 1, sense strand); 5’-
CTTGGTTCTGTTTTCTTCAACTTCGACTTATCGAATTTC
TC GATCTCAGCCATATCGGGTTTGTCAGACATC–3’ 
(Tβ4 reporter 1, antisense strand); 5’-
CAAGGATGGCAGACAAGCCGGACATGGGGGAAATCGCCA
GCTT CGATAAGGCCAAGTTGAAGAAAACCGAGC-3’ (Tβ10 
reporter 1, sense strand); 5’-
CTTGGCTCGGTTTTCTTCAACTTGGCCTTATCGAAGCT    
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GGCGATTTCCCC CATGTCCGGCTTGTCTGCCATC–3’ 
(Tβ10 reporter 1, antisense strand); 5’- 
CAAGGTCAAAAGAAACAATTGAACAAGAGAAGCAA
GCTGGCGAATCGTAATGAGGCGAGCGCCGCCAATAT
C–3’ (Tβ4 reporter 2, sense strand); 5’-
CTTGGATATTGGCGGCGCTCGCCTCATTACGATTCGCC
AGCTTGCTTCTCTTGTTCAATTGTTTCTTTTGAC–3’  (Tβ4 
reporter 2, antisense strand); 5’- 
CAAGGACCAAAGAGACCATTGAACAGGAAAAGAGG
AGTGAAATCTCCTAAAAGCCTAGGAAGATTTCCCCAC
–3’ (Tβ10, reporter 2, sense strand); 5’- 
CTTGGTGGGGAAATCTTCCTAGGCTTTTAGGAGATTTC
ACTCCTCTTTTCCTGTTCAATGGTCTCTTTGGTC–3’ (Tβ10 
reporter 2, antisense strand). Oligonucleotides were 
annealed as described above and ligated into the StyI site 
of pGL2-Basic (Promega). To enable a high level of basal 
expression, the SV40 promoter of pGL2-Control 
(Promega) was subcloned as a Hind III/Kpn I fragment 
into the pGL2-Basic polylinker, upstream of the target 
sequences. 
 
Culture and transfection of NIH-3T3 cells 
 
All cell culture reagents were from Invitrogen. Cells were 
maintained in DMEM, supplemented with 10% (w/v) 
bovine calf serum, 100units/ml penicillin and 100µg/ml 
streptomycin, at 37°C in a humidified 5% CO2/air 
atmosphere. Cells were transfected with the shRNA or 
co-transfected with shRNA and reporter constructs, 
using Effectene (Qiagen) transfection reagent. 2.1 x 105 
cells were cultured overnight to 50-70% confluence and a 
total of 500ng DNA added per well. A pCMV-β-gal 
plasmid was also included as a marker of transfection 
efficiency. Duplicate transfections were performed in 
each experiment and data pooled from four independent 
experiments. 
 
Luciferase reporter assays 
 
Cells were harvested 48 hours post-transfection and 
assayed using Promega’s Luciferase Assay System. Cells 
were washed once in PBS, scraped into 400µl of reporter 
lysis buffer and lysis facilitated by two rounds of 
freezing (-80°C) and thawing (37°C). 20µl lysate were 
combined with 100µl assay reagent and luciferase 
activity measured using a TD-20/20 Luminometer 
(Turner Designs). To normalize for transfection 
efficiency, the activity of co-transfected β-galactosidase 
was also assayed. 100µl of lysate were combined with 
50µl of lysis buffer and 150µl of 2x β-galactosidase assay 
buffer and incubated at 37°C for 20-90 minutes until the 
yellow  ο-nitrophenyl was produced. The reaction was 
terminated by the addition of 1M Na2CO3 and the 
absorbance at 420nm recorded. 
 
RESULTS AND DISCUSSION 
 
We sought to target Thymosin β4, which encodes an actin-
binding protein implicated in cell movement, using 
RNAi. Tβ4, the predominant mammalian isoform of the 
β-thymosin family, shares a high degree of homology 
with other isoforms, such as Tβ10 and Tβ9 (12). Tβ10 is 
the  β-thymosin most closely related to Tβ4, displaying 
70.4% identity within the coding region. The coding 
region for both Tβ4 and Tβ10 is only 135bp and as such 
there is limited potential to design a Tβ4-specific siRNA 
that will not cross-react with Tβ10. Intronic sequences are 
ordinarily avoided since these immature mRNAs will be 
kept in the nucleus while RNAi mediated mRNA 
degradation is believed to occur predominantly in the 
cytoplasm (13). 3’ and 5’ untranslated regions tend to be 
avoided since they may be bound by regulatory proteins 
and thus be inaccessible to siRNAs or RISC. Further 
limitations are imposed by the need to adopt established 
criteria for optimal siRNA design (14). 
 
Sense and antisense Tβ4 sequences of 23 base pairs in 
length, separated by a nine bp spacer, were introduced 
downstream of the H1 RNA pol III promoter (11, 15), 
followed by a stretch of five thymidines which act to 
terminate transcription. Two sequence stretches were 
selected, as regions displaying minimum sequence 
identity with Tβ10; Tβ4shRNA1 incorporated six 
mismatches and Tβ4shRNA2 twelve mismatches versus 
Tβ10, as shown in Figure 1. The mismatches lie 
predominantly in the center of the shRNAs, with 
additional mismatches at the 5’ end of Tβ4shRNA1 and 
at both extremes of Tβ4shRNA2. The position of a 
mismatch has been shown to be a critical factor in RNAi 
selectivity, with mismatches at the 5’ end more readily     
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tolerated than those at the 3’ end (16). Given the number 
and positions of the mismatches, neither Tβ4shRNA 
would be predicted to cross-react with Tβ10. Constructs 
were evaluated by transient transfection of NIH-3T3 
cells. We encountered considerable difficulty when 
attempting to demonstrate the specificity of Tβ4 RNAi. 
While northern blotting appeared to show down-
regulation of Tβ4 (to 21% of the level in non-transfected 
cells), re-probing of the blot for Tβ10 levels revealed 
bands of equivalent size and signal intensities as seen for 
Tβ4. Due to the significant level of identity shared by 
these two genes, the Tβ10 probe was able to cross-react 
with the more abundant Tβ4 transcript, which is 
comparable in size. Quantitative Real Time RT-PCR 
proved equally uninformative; although specific 
products could be amplified for Tβ4 and Tβ10, the degree 
of  Tβ4 knockdown revealed by this technique was 
modest, likely due to the sensitivity in detecting 
expression in cells which failed to transfect with the 
shRNA constructs (estimated to be as high as 40%).  
  
The need for a more sensitive means of determining 
RNAi specificity led us to develop a reporter-based assay 
for RNAi, as outlined in Figure 2. Our assay is based 
upon the introduction of target sequences downstream of 
the luciferase reporter gene. The ability of a 
complementary shRNA to knockdown its target is then 
quantitatively determined by a decrease in luciferase 
activity. Synthetic oligonucleotides containing the 23nt 
target region along with 40nt of flanking sequence were 
designed to produce the appropriate StyI overhangs 
when annealed (Fig. 2). Oligonucleotides were ligated 
into the StyI site located between the splice donor site 
and poly(A) signal of the luciferase gene in pGL2-Basic 
(Promega), resulting in the transcription of a luciferase 
mRNA containing the target sequence. The non-
palindromic nature of the StyI site in pGL2-Basic 
(CCAAGG) ensured that the oligonucleotides were 
ligated into the vector in the desired 5’-3’ orientation. 
The SV40 promoter of pGL2-Control (Promega) was 
introduced as a KpnI/ HindIII fragment into the multiple 
cloning region, to enable strong basal luciferase 
expression. 
Fig. 2: A reporter assay to determine the specificity of RNAi. A. 
Oligonucleotides were synthesized to contain the 23nt shRNA target 
region, 20nt of flanking sequence on each side and appropriate 
nucleotides to generate StyI overhangs. Complementary oligonucleotides 
were annealed and ligated into the StyI  site of pGL2-Basic. The SV40 
promoter of pGL2-Control was subcloned into the KpnI / HindIII sites for 
maximal expression. B. The use of the reporter assay to determine 
whether a gene can be specifically targeted for RNAi (i) and to confirm 
that a closely related gene remains unaffected (ii). The respective Tβ4 
shRNA target sequences and analogous sequences of Tβ10 were 
introduced into reporter constructs as described above. Upon transfection 
into mammalian cells luciferase mRNA is transcribed containing the 
target sequence within the 3’ untranslated region. Translation is 
unaffected by the presence of the target sequence and functional 
luciferase is synthesized. Tβ4 shRNAs, when co-transfected and 
transcribed by H1 polymerase III, direct the RISC towards the 
complementary  Tβ4 target sequence within the luciferase mRNA. 
Degradation of the mRNA ensues, translation does not occur and no 
luciferase activity is detected. A mismatched target sequence (Tβ10) in 
principal is not recognized by the shRNA, the mRNA is translated and 
luciferase activity detected. 
 
Four reporter constructs were created, two of which 
contained the Tβ4 shRNA target regions and the other 
two contained the analogous regions of Tβ10 (see 
alignment, Fig. 1). Co-transfection of Tβ4 reporter 1 with 
the appropriate shRNA (Tβ4shRNA1) resulted in a 
significant knockdown of luciferase activity (by 87%, n=8, 
p<0.0001) compared with the pcDNA3 backbone, 
confirming the efficacy of the shRNA (Fig. 3A). Neither 
of the mismatched shRNAs (Tβ4shRNA2 nor a control 
RasGAP shRNA (11)) affected luciferase activity.     
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Conversely, activity of Tβ4 reporter 2 was selectively 
knocked down by Tβ4shRNA2 (by 89%, n=8, p<0.0001), 
but not by Tβ4shRNA1 (Fig. 3B). Activity of Tβ10 
reporter 1 was unaffected by the Tβ4shRNA1 as 
compared to the RasGAPshRNA control (Fig. 3A) and 
neither, Tβ4shRNA1 nor Tβ4shRNA2 adversely affected 
Tβ10 reporter 2 (Fig. 3B). However, the Tβ4shRNA2 
construct, which contained 12 sequence mismatches to 
the analogous Tβ10 region, reduced Tβ10 reporter 1 
activity (by 42%, n=8, p<0.001; Fig. 3A) compared to the 
pcDNA3 backbone. Given the degree of sequence 
mismatch this was an unexpected, yet significant 
observation since it represents partial silencing of an 
undesired “target.”  This in turn could potentially result 
in a hypomorphic cellular phenotype assuming a dose-
dependent requirement for Tβ10 function.  
 
The reporter assay, therefore, has enabled us to compare 
the potency of shRNAs in inducing RNAi against Tβ4 
and, importantly, to test the selectivity of knockdown of 
each shRNA against Tβ10. This method can be applied to 
all RNAi-based studies in which there is risk of targeting 
homologous genes, particularly when selective 
knockdown has been difficult to prove by conventional 
semi-quantitative assays of gene expression. 
 
The present study exposes a further issue pertaining to 
RNAi, which is that siRNAs do not have to target coding 
region; although this is usually the preferred approach 
(13, 17). Whilst our shRNAs are directed against the 
coding sequence of the gene of interest, the sequence has 
been inserted into the 3’UTR of the luciferase gene, 
where the shRNAs induce degradation of the luciferase 
mRNA. In cases where sequence homology is high 
throughout the coding region and off-target silencing is 
shown to occur, it may become necessary to target the 
more divergent untranslated sequence. It should be 
possible to determine, using reporter constructs based on 
those described herein, whether binding by regulatory 
proteins renders the sequence inaccessible to the RNAi 
machinery upon transfection into the cell type for 
phenotype analysis.  
 
 
Fig. 3: Use of the luciferase reporter assay to determine the specificity of 
Tβ4 shRNA. NIH3T3 cells were transfected with a reporter construct, 
containing either of the Tβ4 target regions or the analogous regions of 
Tβ10 (n=8; duplicates from four independent experiments). The ability of 
the Tβ4 shRNAs to induce RNAi was assessed by co-transfection; 
Tβ4shRNA1, the shRNA complementary to Tβ4 reporter 1, induced an 
87% down-regulation of luciferase activity (p<0.0001), compared with 
empty pcDNA3 control vector (A). Non-complementary shRNAs 
(Tβ4shRNA2 or a control RasGAPshRNA (11) did not significantly reduce 
luciferase activity. Similarly, Tβ4shRNA2 selectively induced an 89% 
reduction of the luciferase activity of Tβ4 reporter 2 (p<0.0001, B) The 
specificity of Tβ4 RNAi derived from Tβ4shRNA1 was confirmed by 
transfection of either of the Tβ10 reporter constructs, the expression of 
which was not significantly decreased. 
 
The use of a reporter gene assay offers a rapid and 
reliable means of quantitatively assessing the potency 
and specificity of RNAi. With the approach described 
here, the generation of constructs is straightforward, 
relying on the use of synthetic oligonucleotides and a 
single restriction site that ensures directional cloning. 
Assaying reporter activity requires little effort and 
unequivocal data can be rapidly obtained, enabling 
immediate progression to the next experimental stage. 
Not all siRNAs are equally effective in inducing RNAi 
and much optimization is often required. Using a 
reporter approach, multiple siRNAs, directed towards     
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the same gene, may be simultaneously assayed and 
quantitatively compared. 
 
The caveats in specificity of gene silencing by RNAi 
means there is an absolute requirement to test the 
selectivity of a siRNA before embarking on phenotype 
analysis. Previous use of reporter assays, with respect to 
RNAi, has enabled the testing of general knockdown (18-
20), but the method has not been applied as a test for 
specificity. The comparison in this study of two closely 
related β-thymosin genes is testament to the sensitivity 
of this approach for determining RNAi specificity. The 
observation that one of our Tβ4 shRNA constructs 
induced 42% knock-down of a Tβ10 reporter, despite 
significant mismatches in sequence, further underscores 
the need for an assessment of the specificity of multiple 
shRNAs. Despite the fact that the gene most closely 
related to Tβ4 was unaffected by the Tβ4shRNA1 
construct, we cannot fully exclude the possibility that 
there are other genes in the genome which can be 
silenced by this construct. That said, use of this assay in 
conjunction with optimal siRNA design, the testing of 
several different siRNAs for equivalent phenotypic 
outcome and identification of RNAi triggers at lowest 
possible concentration (21) should significantly improve 
confidence in the specificity of gene knockdown. 
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